Shares of Oxford Biomedica plc (LON:OXB - Get Free Report) shot up 12.1% on Thursday . The company traded as high as GBX 280 ($3.69) and last traded at GBX 260.60 ($3.44). 152,699 shares traded hands during mid-day trading, a decline of 50% from the average session volume of 303,133 shares. The stock had previously closed at GBX 232.50 ($3.07).
Oxford Biomedica Stock Performance
The company has a debt-to-equity ratio of 166.48, a quick ratio of 1.67 and a current ratio of 2.35. The firm's 50 day moving average is GBX 314.40 and its two-hundred day moving average is GBX 377.93. The stock has a market capitalization of £319.97 million, a PE ratio of -2.24 and a beta of 1.09.
Oxford Biomedica (LON:OXB - Get Free Report) last posted its quarterly earnings data on Wednesday, April 9th. The biopharmaceutical company reported GBX (41.75) (($0.55)) earnings per share for the quarter. Oxford Biomedica had a negative net margin of 145.98% and a negative return on equity of 202.50%. As a group, research analysts predict that Oxford Biomedica plc will post -31.0799998 earnings per share for the current year.
About Oxford Biomedica
(
Get Free Report)
Oxford Biomedica LSE: OXB is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.
Read More
Before you consider Oxford Biomedica, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oxford Biomedica wasn't on the list.
While Oxford Biomedica currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
